About the effects and efficacy of Ruxolitinib cream-Opzelura

Ruxolitinib cream (Ruxolitinib cream)-Opzelura is an innovative drug specifically used to treat some autoimmune skin diseases. Its main ingredient, ruxolitinib, is a selective Janus kinase (JAK) inhibitor that can effectively inhibit the activities of JAK1 and JAK2. These enzymes play key roles in cell signaling and are particularly closely related to the signaling pathways of various cytokines and growth factors. The JAK signaling pathway is not only involved in the regulation of immune responses, but also has an important impact on the hematopoietic process.

Under normal physiological conditions, cytokines activateJAK enzymes by binding to their receptors, thereby initiating a series of signal transduction processes, ultimately leading to the recruitment and activation of STATs (signal transducers and activators of transcription). Activated STAT will be transferred to the nucleus and regulate the expression of specific genes. However, in some disease states, such as vitiligo, the immune system is abnormally active, leading to an attack on melanocytes. In this process, interferon-γ (IFN-γ) is considered a key mediator, which plays an important role in promoting immune cell activation and attacking melanocytes.

Ruxolitinib reduces the signaling triggered by IFN-γ by blockingJAK1 and JAK2, thereby reducing the immune system's ability to destroy melanocytes. This mechanism allows melanocytes to better survive and resume function, thereby reproducing pigment and improving the appearance of the skin. Clinical studies have shown that patients using ruxolitinib ointment make significant progress in pigment restoration, and many are even able to see significant improvements in skin color.

In addition, the topical application form of ruxolitinib ointment allows the drug to act directly on the area that needs treatment, which not only enhances the therapeutic effect, but also significantly reduces the risk of systemic side effects. This local treatment modality offers patients a safe and effective option, especially for those who cannot tolerate traditional systemic treatments.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura